Exploring beyond clinical routine SARS-CoV-2 serology using MultiCoV-Ab to evaluate endemic coronavirus cross-reactivity

Matthias Becker, Monika Strengert, Daniel Junker, Philipp D. Kaiser, Tobias Kerrinnes, Bjoern Traenkle, Heiko Dinter, Julia Häring, Stéphane Ghozzi, Anne Zeck, Frank Weise, Andreas Peter, Sebastian Hörber, Simon Fink, Felix Ruoff, Alex Dulovic, Tamam Bakchoul, Armin Baillot, Stefan Lohse, Markus Cornberg, Thomas Illig, Jens Gottlieb, Sigrun Smola, André Karch, Klaus Berger, Hans-Georg Rammensee, Katja Schenke-Layland, Annika Nelde, Melanie Märklin, Jonas S. Heitmann, Juliane S. Walz, Markus Templin, Thomas O. Joos, Ulrich Rothbauer, Gérard Krause and Nicole Schneiderhan-Marra ()
Additional contact information
Matthias Becker: NMI Natural and Medical Sciences Institute at the University of Tübingen
Monika Strengert: Helmholtz Centre for Infection Research
Daniel Junker: NMI Natural and Medical Sciences Institute at the University of Tübingen
Philipp D. Kaiser: NMI Natural and Medical Sciences Institute at the University of Tübingen
Tobias Kerrinnes: Helmholtz-Institute for RNA-based Infection Research (HIRI)
Bjoern Traenkle: NMI Natural and Medical Sciences Institute at the University of Tübingen
Heiko Dinter: NMI Natural and Medical Sciences Institute at the University of Tübingen
Julia Häring: NMI Natural and Medical Sciences Institute at the University of Tübingen
Stéphane Ghozzi: Helmholtz Centre for Infection Research
Anne Zeck: NMI Natural and Medical Sciences Institute at the University of Tübingen
Frank Weise: NMI Natural and Medical Sciences Institute at the University of Tübingen
Andreas Peter: University Hospital Tübingen
Sebastian Hörber: University Hospital Tübingen
Simon Fink: NMI Natural and Medical Sciences Institute at the University of Tübingen
Felix Ruoff: NMI Natural and Medical Sciences Institute at the University of Tübingen
Alex Dulovic: NMI Natural and Medical Sciences Institute at the University of Tübingen
Tamam Bakchoul: University Hospital Tübingen
Armin Baillot: Niedersächsisches Landesgesundheitsamt, Department of Virology/Serology
Stefan Lohse: Saarland University Medical Center
Markus Cornberg: Hannover Medical School, Hannover, Germany; Centre for Individualized Infection Medicine (CiiM)
Thomas Illig: Hannover Unified Biobank (HUB), Hannover Medical School
Jens Gottlieb: Hannover Medical School
Sigrun Smola: Saarland University Medical Center
André Karch: University of Münster
Klaus Berger: University of Münster
Hans-Georg Rammensee: University of Tübingen
Katja Schenke-Layland: NMI Natural and Medical Sciences Institute at the University of Tübingen
Annika Nelde: University of Tübingen
Melanie Märklin: Cluster of Excellence iFIT (EXC2180) “Image-Guided and Functionally Instructed Tumor Therapies”, University of Tübingen
Jonas S. Heitmann: Cluster of Excellence iFIT (EXC2180) “Image-Guided and Functionally Instructed Tumor Therapies”, University of Tübingen
Juliane S. Walz: University of Tübingen
Markus Templin: NMI Natural and Medical Sciences Institute at the University of Tübingen
Thomas O. Joos: NMI Natural and Medical Sciences Institute at the University of Tübingen
Ulrich Rothbauer: NMI Natural and Medical Sciences Institute at the University of Tübingen
Gérard Krause: Helmholtz Centre for Infection Research
Nicole Schneiderhan-Marra: NMI Natural and Medical Sciences Institute at the University of Tübingen

Nature Communications, 2021, vol. 12, issue 1, 1-12

Abstract: Abstract The humoral immune response to SARS-CoV-2 is a benchmark for immunity and detailed analysis is required to understand the manifestation and progression of COVID-19, monitor seroconversion within the general population, and support vaccine development. The majority of currently available commercial serological assays only quantify the SARS-CoV-2 antibody response against individual antigens, limiting our understanding of the immune response. To overcome this, we have developed a multiplex immunoassay (MultiCoV-Ab) including spike and nucleocapsid proteins of SARS-CoV-2 and the endemic human coronaviruses. Compared to three broadly used commercial in vitro diagnostic tests, our MultiCoV-Ab achieves a higher sensitivity and specificity when analyzing a well-characterized sample set of SARS-CoV-2 infected and uninfected individuals. We find a high response against endemic coronaviruses in our sample set, but no consistent cross-reactive IgG response patterns against SARS-CoV-2. Here we show a robust, high-content-enabled, antigen-saving multiplex assay suited to both monitoring vaccination studies and facilitating epidemiologic screenings for humoral immunity towards pandemic and endemic coronaviruses.

Date: 2021
References: Add references at CitEc
Citations:

Downloads: (external link)
https://www.nature.com/articles/s41467-021-20973-3 Abstract (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:natcom:v:12:y:2021:i:1:d:10.1038_s41467-021-20973-3

Ordering information: This journal article can be ordered from
https://www.nature.com/ncomms/

DOI: 10.1038/s41467-021-20973-3

Access Statistics for this article

Nature Communications is currently edited by Nathalie Le Bot, Enda Bergin and Fiona Gillespie

More articles in Nature Communications from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().